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technical importance is the RT field arrangement, where the 
trend is using more complex dose planning. However, in the 
complex IMRT plans often more low-dose is distributed into 
large volumes of organs at risk, and that may be a bad 
decision increasing the risk of late morbidity. More patients 
are receiving adjuvant systemic therapies today compared to 
previously, and these therapies may partly reduce the gain 
from RT because they themselves reduce the risk of LRR, and 
partly because they may increase the risk of late morbidity 
after RT. This may be the case for RT-related morbidities like 
the risk of ischemic heart disease, damage to the brachial 
plexus, risk of lymph oedema and impaired shoulder 
movement. The risk of RT-induced second cancer is also 
important since it may be as high as 1:200, thus of the same 
magnitude as the risk of RT-induced heart disease (Grantzau 
et al, R&O, 2013). 
In conclusion, new studies are now supporting earlier studies 
showing gain from regional RT also in pN1 patients, but there 
is still a risk of RT related morbidity which must be dealt 
with. Therefore we need focus on identifying those patients 
who benefit from the RT, and we need a solid basis for 
selecting those patients who can be spared from RT. Studies 
on gene risk profiles to help us identify patients with benefit 
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SBRT for lung tumors has become an effective and safe 
routine procedure in many centers. However, due to 
historical developments, there is still a large diversity in 
doses and fractionation regimens. 
In this teaching lecture, an overview of current dose and 
fractionation regimens for different clinical scenarios of lung 
SBRT will be given and discussed in the light of outcome and 
normal tissue toxicity.  
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Classically detector response in small fields was considered 
to be influenced by two key factors: volume-averaging and 
differences between the photon spectra of small and large 
fields. Therefore it was thought that an ideal detector should 
be small in comparison to the dimensions of the fields it was 
used to measure, and have an atomic composition similar to 
water so that detector response would vary with fluence 
spectrum in the same way as dose-to-water. Consequently 
small air ion chambers and diamond detectors were 
identified as promising small field dosimeters.  
For some time it has also been known that differences 
between the fluence spectra of small and intermediate (4×4 
cm2) fields are insufficiently large to generate appreciable 
variations in the response of silicon-based detectors relative 
to water, and thus that diode detectors may be another good 
option for small field dosimetry, provided their calibration is 
‘daisy-chained’ from the usual 10×10 cm2 reference fields via 
a 3×3 or 4×4 cm2 intermediate. 
More recently it has been understood that as lateral 
electronic equilibrium (LEE) begins to break down (in fields 
narrower than 1.5 cm for a 6 MV beam) so response begins to 
be substantially influenced by the density of the detector 
sensitive volume (Figure 1), a non-classical factor which has 
no impact on response in wider fields. This finding has two 
implications for small field dosimetry: (i) it allows a small 
field to be defined physically as one in which LEE does not 
hold, rather than operationally with respect to detector size; 
(ii) it raises questions about the optimality of some air ion 
chambers, diodes and diamond detectors for small field 
dosimetry, as the sensitive volumes of these detectors have 
densities .001, 2.3 and 3.5 that of water, and it suggests that 
liquid ion chambers and plastic scintillators with roughly unit 
densities may make better detectors. 
Very recently, however, it has been appreciated that 
response is influenced not just by the density of a detector 
sensitive volume, but also by the densities of detector 
components lying close to it; and therefore that the response 
of diodes, diamond detectors, and potentially air ion 
chambers in small fields can be improved by using density 
compensation. In the case of a solid-state detector this 
involves building a small air cavity into the detector, 
upstream of the sensitive volume. In this lecture more details 
are provided of detector response in small fields and the 
factors underlying it. Density compensation techniques are 
also outlined, and results from an evaluation of a prototype 
density-compensated PTW diode-Air detector are presented. 
